You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,811,248


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,811,248
Title: Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
Abstract:An antigen comprising 5,7 cholestadien-3.beta.-ol (7-dehydrocholesterol) or a compound having a structure similar to 5,7 cholestadien-3.beta.-ol and a quaternary ammonium salt is provided. Also provided is a method of generating an antibody using the aforementioned antigen, as well as antibodies produced thereby and fragments of such antibodies. The invention also provides a rat myeloma cell line Z2D3 73/30 1D10 and a murine-human chimeric monoclonal antibody produced thereby. A CDR-grafted antibody comprising a CDR region amino acid sequence from hybridoma Z2D3 or hybridoma Z2D3/3E5 and framework and constant region amino acid sequences from a human immunoglobulin is further provided. Also provided are methods for imaging atherosclerotic plaque, ablating atherosclerotic plaque, detecting and quantitatively determining in a sample an antigen indicative of the presence of atherosclerotic plaque, reducing the amount of atherosclerotic plaque in a blood vessel, and treating atherosclerosis in a subject. The invention also provides peptides having amino acid sequences which are the same or substantially the same as those of the aforementioned murine-human chimeric monoclonal antibody, as well as isolated nucleic acid sequences encoding therefore.
Inventor(s): Ditlow; Charles C. (Fremont, CA), Chen; Francis W. (San Francisco, CA), Calenoff; Emanuel (Chicago, IL)
Assignee: Charter Ventures (Palo Alto, CA)
Application Number:08/480,434
Patent Claims:1. A proteinaceous construct capable of specifically binding to atherosclerotic plague comprising a binding site which comprises an amino acid sequence or combination of amino acid sequences, each of which amino acid sequences is the same or substantially the same as the amino acid sequence of a complementarity determining region (CDR) of a murine-human chimeric monoclonal antibody produced by a rat myeloma cell line designated Z2D3 73/30 1D10.

2. The proteinaceous construct of claim 1, labeled with a detectable marker.

3. The proteinaceous construct of claim 1 bound to a solid support.

4. A reagent for use in imaging atherosclerotic plaque, which comprises the proteinaceous construct of claim 2, in an amount effective to image atherosclerotic plaque, and a physiologically acceptable carrier.

5. A method for imaging atherosclerotic plaque, which comprises:

(a) contacting the atherosclerotic plaque to be imaged with the reagent of claim 4, under conditions such that the reagent binds to the atherosclerotic plaque; and

(b) detecting the detectable marker labelling the proteinaceous construct in the reagent bound to the atherosclerotic plaque;

thereby imaging the atherosclerotic plaque.

6. The proteinaceous construct of claim 1, bound to a chromophore capable of absorbing radiation having a plaque ablating wavelength.

7. The proteinaceous construct of claim 6, wherein the chromophore absorbs light having a wavelength from about 190 nm to about 1100 nm.

8. The proteinaceous construct of claim 7, wherein the chromophore is fluorescein, rhodamine, tetracycline, hematoporphyrin, or .beta.-carotene.

9. A reagent for ablating atherosclerotic plaque comprising the proteinaceous construct of claim 6 in an amount effective to highlight the atherosclerotic plaque to be ablated, and a physiologically acceptable carrier.

10. A method for ablating atherosclerotic plaque, which comprises:

(a) contacting atherosclerotic plaque with an effective amount of the reagent of claim 9, so that the proteinaceous construct present in the reagent binds to the atherosclerotic plaque forming an atherosclerotic plaque-construct complex;

(b) exposing the resulting complex to radiation having a plaque ablating wavelength under conditions such that the radiation is absorbed by the chromophore at a sufficient energy to ablate the atherosclerotic plaque; and

(c) thereby ablating the atherosclerotic plaque.

11. A method for detecting in a sample an antigen indicative of the presence of atherosclerotic plaque, which comprises:

(a) contacting the sample with the proteinaceous construct of claim 1, under conditions such that the proteinaceous construct binds to the antigen in the sample to form a detectable complex;

(b) detecting the complex so formed; and

(c) thereby detecting in the sample an antigen indicative of the presence of atherosclerotic plaque.

12. A method for quantitatively determining in a sample the concentration of an antigen indicative of the presence of atherosclerotic plaque, which comprises:

(a) contacting a solid support with an excess of the proteinaceous construct of claim 1, under conditions permitting the construct to attach to the surface of the solid support;

(b) removing unbound proteinaceous construct;

(c) contacting the resulting solid support to which the proteinaceous construct is bound with the sample under conditions such that any antigen present in the sample binds to the bound construct and forms a complex therewith;

(d) removing any antigen which is not bound to the complex;

(e) contacting any complex so formed with an excess of a detectable reagent which specifically binds to any antigen present in the complex so as to form a second complex which includes the proteinaceous construct, the antigen, and the detectable reagent;

(f) removing any detectable reagent which is not bound in the second complex;

(g) quantitatively determining the concentration of detectable reagent present in the second complex; and

(h) thereby quantitatively determining in the sample the concentration of an antigen indicative of the presence of atherosclerotic plaque.

13. The method of claim 12, wherein the detectable reagent comprises a monoclonal antibody or fragment thereof labeled with a detectable marker, wherein the monoclonal antibody is produced by hybridoma Z2D3 having ATCC Accession Number HB9840, hybridoma Z2D3/3E5 having ATCC Accession Number HB10485, rat myeloma cell line Z2D3 73/30 1D10 having ATCC Accession Number CRL 11203, or a CDR-grafted antibody comprising a CDR region from hybridoma Z2D3 or hybridoma Z2D3/3E5 and a framework and constant region from a human immunoglobulin.

14. A method for quantitatively determining in a sample the concentration of an antigen which is indicative of the presence of atherosclerotic plaque, which comprises:

(a) contacting a solid support with a predetermined amount of the proteinaceous construct of claim 1, under conditions permitting the construct to attach to the surface of the solid support;

(b) removing any proteinaceous construct not bound to the solid support;

(c) contacting the resulting solid support to which the construct is bound with a predetermined amount of an antigen labeled with a detectable marker, and with the sample under such conditions that labeled and sample antigens competitively bind to the construct bound to the solid support and form a complex therewith;

(d) removing any labeled and sample antigens which are not bound to the complex;

(e) quantitatively determining the amount of labeled antigen bound to the solid support; and

(f) thereby quantitatively determining in the sample the concentration of an antigen which is indicative of the presence of atherosclerotic plaque.

15. The method of claim 14, wherein step (e) comprises quantitatively determining the amount of labeled antigen not bound to the solid support.

16. A method for quantitatively determining in a sample the concentration of an antigen which is indicative of the presence of atherosclerotic plaque, which comprises:

(a) contacting a solid support with a predetermined amount of the proteinaceous construct of claim 1, under conditions permitting the construct to attach to the surface of the support;

(b) removing any proteinaceous construct not bound to the solid support;

(c) contacting the resulting solid support to which the construct is bound with the sample under conditions such that any antigen present in the sample binds to the bound construct and forms a complex therewith;

(d) removing any antigen which is not bound to the complex;

(e) contacting the complex so formed with a predetermined amount of plaque antigen labeled with a detectable marker under conditions such that the labeled plaque antigen competes with the antigen from the sample for binding to the construct;

(f) removing any labeled and sample antigens which are not bound to the complex;

(g) quantitatively determining the amount of labeled plaque antigen bound to the solid support; and

(h) thereby quantitatively determining in the sample the concentration of an antigen which is indicative of the presence of atherosclerotic plaque.

17. The method of claim 16, wherein step (g) comprises quantitatively determining the amount of labeled antigen not bound to the solid support.

18. The proteinaceous construct of claim 1, conjugated to an enzyme capable of digesting a component of atherosclerotic plaque.

19. The proteinaceous construct of claim 18, wherein the enzyme is a proenzyme which, when activated, is converted to an enzyme capable of digesting a component of atherosclerotic plaque.

20. The proteinaceous construct of claim 18, wherein the construct and the enzyme comprise a single molecule.

21. The proteinaceous construct of claim 18, wherein the construct is a bifunctional peptide comprising a binding site specific for the enzyme and a binding site specific for the antigen.

22. The proteinaceous construct of claim 18, wherein the enzyme is a proteinase, an elastase, a collagenase, or a saccharidase.

23. The proteinaceous construct of claim 19, wherein the proenzyme is a proenzyme form of fibroblastic collagenase, gelatinase, polymorphonuclear collagenase, granolocytic collagenase, stromelysin I, stromelysin II, or elastase.

24. A method for reducing the amount of atherosclerotic plaque in a blood vessel, which comprises:

(a) contacting the atherosclerotic plaque with a reagent comprising the proteinaceous construct of claim 18 under conditions and in an amount such that the reagent binds to, and digests, a component of the plaque; and

(b) thereby reducing the amount of atherosclerotic plaque in a blood vessel.

25. A reagent comprising the proteinaceous construct of claim 18, in an amount effective to digest a component of atherosclerotic plaque, and a physiologically acceptable carrier.

26. The proteinaceous construct of claim 1, conjugated to cell growth inhibitors capable of preventing proliferation of atherosclerotic plaque.

27. A pharmaceutical composition for treating atherosclerosis, which comprises the proteinaceous construct of claim 1 bound to a drug useful in treating atherosclerosis.

28. A method of treating atherosclerosis in a subject, which comprises administering to the subject an amount of the pharmaceutical composition of claim 27 effective to treat atherosclerosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.